Contact
searchSearch
HMP Global
Login

Cutaneous Squamous Cell Carcinoma Excellence Forum

Cutaneous Squamous Cell Carcinoma
Excellence Forum

Shannon Trotter, DO, DOCS Dermatology
Videos
Managing Patients With Cutaneous Squamous Cell Carcinoma
09/05/2025
Shannon Trotter, DO
Shannon Trotter, DO, discusses the challenges that arise when managing patients with cutaneous squamous cell carcinoma, touching on risk stratification, multidisciplinary collaboration, and gene expression profiling.
Shannon Trotter, DO, discusses the challenges that arise when managing patients with cutaneous squamous cell carcinoma, touching on risk stratification, multidisciplinary collaboration, and gene expression profiling.
Shannon Trotter, DO, discusses...
09/05/2025
Oncology
Shannon Trotter, DO, DOCS Dermatology
Videos
Challenges in Risk Stratification for Patients With Cutaneous Squamous Cell Carcinoma
09/02/2025
Shannon Trotter, DO
Shannon Trotter, DO, discusses the discrepancies that can arise when risk stratifying patients with cutaneous squamous cell carcinoma.
Shannon Trotter, DO, discusses the discrepancies that can arise when risk stratifying patients with cutaneous squamous cell carcinoma.
Shannon Trotter, DO, discusses...
09/02/2025
Oncology
Quiz
The Relationship Between Recessive Dystrophic Epidermolysis Bullosa and Cutaneous Squamous Cell Carcinoma
08/07/2025
What is the relationship between recessive dystrophic epidermolysis bullosa and cutaneous squamous cell carcinoma? Take our quick quiz to find out!
What is the relationship between recessive dystrophic epidermolysis bullosa and cutaneous squamous cell carcinoma? Take our quick quiz to find out!
What is the relationship between...
08/07/2025
Oncology
Andrew South, PhD, University of Wisconsin-Madison
Videos
The Potential of Rigosertib in RDEB-Associated Cutaneous Squamous Cell Carcinoma
07/22/2025
Andrew South, PhD
Andrew South, PhD, discusses the results of 2 trials investigating the use of rigosertib among patients with RDEB-associated cutaneous squamous cell carcinoma.
Andrew South, PhD, discusses the results of 2 trials investigating the use of rigosertib among patients with RDEB-associated cutaneous squamous cell carcinoma.
Andrew South, PhD, discusses the...
07/22/2025
Oncology
Andrew South, PhD, University of Wisconsin-Madison
Videos
The Potential of Rigosertib in RDEB-Associated Cutaneous Squamous Cell Carcinoma
07/22/2025
Andrew South, PhD
Andrew South, PhD, discusses the use of rigosertib among patients with RDEB-associated cutaneous squamous cell carcinoma.
Andrew South, PhD, discusses the use of rigosertib among patients with RDEB-associated cutaneous squamous cell carcinoma.
Andrew South, PhD, discusses the...
07/22/2025
Oncology
Georgina Long, MBBS, PhD, Melanoma Institute Australia
Videos
Neoadjuvant Nivolumab Plus Relatlimab for Resectable Cutaneous Squamous Cell Carcinoma
06/17/2025
Georgina Long, MBBS, PhD
Georgina Long, MBBS, PhD, describes the Neo-SCC trial, an investigator-led trial that is currently ongoing.
Georgina Long, MBBS, PhD, describes the Neo-SCC trial, an investigator-led trial that is currently ongoing.
Georgina Long, MBBS, PhD,...
06/17/2025
Oncology
Dan Zandberg, MD, UPMC Hillman Cancer Center
Videos
Cetuximab Plus Avelumab for Patients With Advanced Cutaneous Squamous Cell Carcinoma
06/17/2025
Daniel Zandberg, MD
Dan Zandberg, MD, discusses results from a phase 2 trial evaluating combination cetuximab-avelumab for advanced cutaneous squamous cell carcinoma.
Dan Zandberg, MD, discusses results from a phase 2 trial evaluating combination cetuximab-avelumab for advanced cutaneous squamous cell carcinoma.
Dan Zandberg, MD, discusses...
06/17/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use